• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

    8/6/24 7:00:09 AM ET
    $OMGA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OMGA alert in real time by email
    • Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024
    • Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expression
    • Strengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors

    CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.

    "We are excited by the meaningful progress achieved to date with our MYCHELANGELO™ I trial, having generated clinical proof-of-platform data that validates the potential of epigenomic controllers as a new class of programmable mRNA therapeutics. As we approach identification of the recommended dose for expansion for OTX-2002, we look forward to sharing updated dose escalation data and initiating expansion cohorts in monotherapy and combination settings in the fourth quarter of this year," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "We are equally energized by the advances we have made with the OMEGA platform, including new preclinical data presented at this year's ASGCT Annual Meeting showing durable and robust upregulation of gene expression with epigenomic controllers across a broad range of targets. We believe these achievements underscore the potential of our platform to create tremendous value through its ability to prospectively engineer epigenomic controllers with diverse and meaningful therapeutic applications across nearly any human disease."

    Recent Highlights and Key Anticipated Milestones

    Development Pipeline and Platform

    • Progressed dose escalation portion of Phase 1/2 MYCHELANGELO™ I clinical trial evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC): Made steady progress towards identifying the recommended dose for expansion (RDE) of OTX-2002, with patient enrollment ongoing in Cohort 6 at the 0.2 mg/kg dose level across sites in the U.S. and Asia. The Company expects to report updated clinical data and is planning for expansion into monotherapy and combination settings in the fourth quarter of 2024.
    • Presented new preclinical data demonstrating durable upregulation of gene expression at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting: Data demonstrated durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanisms, including turning on inactive genes, augmenting expression of genes with existing but low baseline expression levels, and increasing expression of poised genes that are typically only responsive to certain external stimuli. Additional data showed reversible downregulation and multiplexed upregulation of gene expression. These findings further demonstrate the OMEGA platform's potential to engineer an entirely novel therapeutic modality to directly target key drivers of disease across therapeutic areas.
    • Continued to advance and enhance the OMEGA platform: The Company is evaluating multiple epigenomic controller programs in preclinical studies, including OTX-2101 for non-small cell lung cancer (NSCLC), an HNF4A program in liver regeneration, and development of an epigenomic controller for the management of obesity in collaboration with Novo Nordisk. Core work on platform biology, epigenomic controller design, and characterization of LNP delivery to the lung and other high-value tissues continues to progress.

    Corporate

    • Strengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors: Dr. Certel is a seasoned biopharmaceutical leader and is responsible for Omega's global business development activities, including strategic partnerships. Mr. Kender brings extensive expertise across corporate finance, business development and corporate licensing, among other roles he held during his career in the pharmaceutical industry, including 35 years spent at Merck & Co., Inc.

    Second Quarter 2024 Financial Results

    As of June 30, 2024, the Company had cash and cash equivalents totaling $45.9 million, which is expected to fund operations into Q1 2025.

    Research and development (R&D) expenses for the second quarter of 2024 were $12.9 million, compared to $25.0 million for the second quarter of 2023. The $12.1 million decrease in R&D expenses was primarily driven by a decrease in external research costs, contract manufacturing costs, and personnel-related expenses.

    General and administrative (G&A) expenses for the second quarter of 2024 were $5.8 million, compared to $6.6 million for the second quarter of 2023. The $0.8 million decrease in G&A expenses was primarily driven by a decrease in personnel-related expenses and consulting and professional fees.

    Net loss for the second quarter of 2024 was $16.3 million, compared to $29.7 million for the second quarter of 2023. The decrease in net loss was driven predominantly by the decrease in R&D expenses.

    About Omega Therapeutics

    Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega's approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions.

    For more information, visit omegatherapeutics.com, or follow us on X and LinkedIn.

            

    About the OMEGA Platform

    The OMEGA platform leverages the Company's deep understanding of gene regulation, genomic architecture and epigenetic mechanisms to design programmable epigenomic mRNA medicines that precisely target and modulate gene expression at the pre-transcriptional level. Combining world-class data science capabilities with rational drug design and customized delivery, the OMEGA platform enables control of fundamental epigenetic processes and reprogramming of cellular physiology to address the root cause of disease. Omega's modular and programmable mRNA medicines, called epigenomic controllers, target specific genomic loci within insulated genomic domains with high specificity to durably tune single or multiple genes to treat and cure diseases through unprecedented precision epigenomic control.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing, progress and design of our ongoing Phase 1/2 MYCHELANGELOTM I clinical trial and our preclinical studies, as well as the timing of announcements of data related thereto; the potential of the OMEGA platform to engineer programmable epigenomic mRNA therapeutics that successfully regulate gene expression by targeting insulated genomic domains; expectations surrounding the potential of our product candidates, including OTX-2002; expectations regarding our pipeline, including trial design, initiation of preclinical studies and advancement of multiple preclinical development programs in oncology, regenerative medicine, and multigenic diseases including inflammatory and cardiometabolic conditions; potential franchise opportunities; our anticipated cash runway into the first quarter of 2025; and upcoming events and presentations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all; the substantial development and regulatory risks associated with epigenomic controllers due to the novel and unprecedented nature of this new category of medicines; our limited operating history; the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future; our need for substantial additional financing; volatility in capital markets and general economic conditions; our investments in research and development efforts that further enhance the OMEGA platform, and their impact on our results; uncertainty regarding preclinical development, especially for a new class of medicines such as epigenomic controllers; potential delays in and unforeseen costs arising from our clinical trials; the fact that our product candidates may be associated with serious adverse events, undesirable side effects or have other properties that could halt their regulatory development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences; difficulties manufacturing the novel technology on which our epigenomic controller candidates are based; our ability to adapt to rapid and significant technological change; our reliance on third parties for the manufacture of materials; our ability to successfully acquire and establish our own manufacturing facilities and infrastructure; our reliance on a limited number of suppliers for lipid excipients used in our product candidates; our ability to advance our product candidates to clinical development; and our ability to obtain, maintain, enforce and adequately protect our intellectual property rights. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    CONTACT

    Investor contact:

    Eva Stroynowski

    617.949.4370

    [email protected]

    Media contact:

    Jason Braco, LifeSci Communications

    646.751.4361

    [email protected]



    Omega Therapeutics, Inc.

    Consolidated statements of operations and comprehensive loss

    (Unaudited, In thousands except share and per share data)
     
     Three Months Ended June 30,  Six Months Ended June 30, 
     2024  2023  2024  2023 
    Collaboration revenue$2,134  $759  $4,494  $1,274 
                
    Operating expenses:           
    Research and development 12,940   25,042   28,355   45,132 
    General and administrative 5,774   6,557   13,170   12,800 
    Total operating expenses 18,714   31,599   41,525   57,932 
    Loss from operations (16,580)  (30,840)  (37,031)  (56,658)
    Other income (expense), net:           
    Interest income, net 299   957   630   1,639 
    Other income (expense), net (24)  196   (33)  53 
    Total other income, net 275   1,153   597   1,692 
    Net loss$(16,305) $(29,687) $(36,434) $(54,966)
    Net loss per common stock attributable to common stockholders, basic and diluted$(0.30) $(0.54) $(0.66) $(1.04)
    Weighted-average common stock used in net loss per share attributable to common stockholders, basic and diluted 55,150,507   55,071,469   55,152,746   52,861,655 
    Comprehensive loss:           
    Net loss$(16,305) $(29,687) $(36,434) $(54,966)
    Other comprehensive income (loss):           
    Unrealized gain on marketable securities —   57   14   308 
    Comprehensive loss$(16,305) $(29,630) $(36,420) $(54,658)





    Omega Therapeutics, Inc.

    Condensed Consolidated Balance Sheets

    (Unaudited, In thousands)
     
     June 30,  December 31,
     2024  2023
    Assets    
    Cash and cash equivalents$45,852  $68,443
    Marketable securities —   4,986
    Other assets 122,373   130,937
    Total assets$168,225  $204,366
    Liabilities and stockholders' equity    
    Liabilities$141,963  $146,350
    Stockholders' equity 26,262   58,016
    Total liabilities and stockholders' equity$168,225  $204,366


    Primary Logo

    Get the next $OMGA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMGA

    DatePrice TargetRatingAnalyst
    11/15/2024Outperform → Mkt Perform
    Raymond James
    6/18/2024$12.00Outperform
    Raymond James
    5/25/2023$18.00 → $15.00Buy
    Jefferies
    12/8/2022$11.00Buy
    H.C. Wainwright
    9/23/2022$12.00Buy
    Chardan Capital Markets
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021$30.00Buy
    Jefferies
    8/24/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $OMGA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results

      Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalitiesBoard has appointed Kaan Certel, Ph.D., as Omega's President and Chief Executive Officer, and Jennifer Nelson, Ph.D., as Chief Scientific OfficerCompany is pursuing strategic partnership opportunities to support dev

      11/14/24 4:05:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio

      Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.

      11/13/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Omega Therapeutics Inc.

      EFFECT - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/26/25 12:15:12 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Omega Therapeutics Inc.

      POS AM - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:04:35 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Omega Therapeutics Inc.

      S-8 POS - Omega Therapeutics, Inc. (0001850838) (Filer)

      3/21/25 4:03:00 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omega Therapeutics downgraded by Raymond James

      Raymond James downgraded Omega Therapeutics from Outperform to Mkt Perform

      11/15/24 9:11:43 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Omega Therapeutics with a new price target

      Raymond James initiated coverage of Omega Therapeutics with a rating of Outperform and set a new price target of $12.00

      6/18/24 7:37:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Omega Therapeutics with a new price target

      Jefferies resumed coverage of Omega Therapeutics with a rating of Buy and set a new price target of $15.00 from $18.00 previously

      5/25/23 7:51:53 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Financials

    Live finance-specific insights

    See more
    • Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

      All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable' target First-known clinical observation of pre-transcriptional gene modulation using a programmable epigenomic mRNA candidate Clinical proof-of-platform established; potential applicability across a broad range of diseases Company to host webcast today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmabl

      9/26/23 7:00:11 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will host a conference call and webcast to discuss preliminary clinical data from the ongoing Phase 1/2 MYCHELANGELO™ I trial of OTX-2002 on Tuesday, September 26, 2023, at 8:00 a.m. ET. The webcast will feature members of Omega's leadership team as well as a moderated discussion with Gerard Evan, Ph.D., Principal Group Leader of the Francis Crick Institute in London and Professor of Cancer Biology, King's College London. The live we

      9/25/23 4:00:32 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Varsalone Jeffrey T

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      2/4/25 9:59:03 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Mehrotra Ravi

      4 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:10:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Mehrotra Ravi

      3 - Omega Therapeutics, Inc. (0001850838) (Issuer)

      12/5/24 4:05:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OMGA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation

      First of its Kind Scientific Collaboration Will Engage Top Research Institutes in Cambridge, UK with Flagship Pioneering Focus on Scaling and Advancing Flagship's Breakthrough Science and Technologies through the Cambridge Life Sciences Ecosystem LONDON, Jan. 23, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement with top life science organisations Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to collaborate to jointly advance breakthrough scientific research and technologies. The

      1/23/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

      CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

      11/20/24 8:00:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer

      Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target   Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced  Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev

      11/20/24 6:30:00 AM ET
      $FHTX
      $MRNA
      $OMGA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OMGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/12/24 12:03:27 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 4:17:05 PM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Omega Therapeutics Inc. (Amendment)

      SC 13G/A - Omega Therapeutics, Inc. (0001850838) (Subject)

      2/9/24 9:28:31 AM ET
      $OMGA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care